Skip to content
Peptideworth
Menu

Goal guide

Peptides for Weight Loss: What the Evidence Actually Shows

Almost every peptide marketed for fat loss has no human weight-loss trial behind it. Four do — and they are the GLP-1 class, which is why they are the only ones a doctor can actually prescribe you for this. Below is what each compound did in trials, in the trial's own numbers, and what happened to the weight afterward.

By Grant Delaney, Research Editor

What actually has evidence behind it

Ordered by how far the published human evidence goes — strongest first. Availability is a separate question from evidence, so it is labeled separately.

  1. Tirzepatide (Zepbound, Mounjaro)

    FDA-approved
    Randomized trials

    Evidence strength: Randomized trials. Randomized controlled trials in humans, at scale.

    What it is
    A single molecule that activates two gut-hormone receptors at once, GIP and GLP-1. It is injected once a week.
    What the evidence shows
    In SURMOUNT-1, 72 weeks of the 15 mg dose produced a mean weight change of −20.9% against −3.1% on placebo, and 91% of people on that dose lost at least 5% of their body weight. A 2026 network meta-analysis of 25 trials put tirzepatide 15 mg first for percentage weight reduction across the whole class.3,5
    The catch
    Gastrointestinal side effects scale with the dose, and the network meta-analysis found they rose with every drug in this class. It is also the class where stopping means regaining — see semaglutide below, where that was measured directly.

    Approved for this use and available by prescription.

  2. Semaglutide (Wegovy, Ozempic)

    FDA-approved
    Randomized trials

    Evidence strength: Randomized trials. Randomized controlled trials in humans, at scale.

    What it is
    A GLP-1 receptor agonist, injected weekly. The most-studied peptide for weight loss by a wide margin.
    What the evidence shows
    STEP 1 ran 1,961 adults for 68 weeks: mean weight change −14.9% on semaglutide 2.4 mg versus −2.4% on placebo, with 50.5% of the treated group losing 15% or more.1,2
    The catch
    The trial extension followed people after they stopped. A year off the drug, they had regained 11.6 of the percentage points they had lost — a 17.3% loss became a 5.6% loss — and most of the cardiometabolic improvements drifted back toward baseline. That is the number to plan around, not the 14.9%.

    Approved for this use and available by prescription.

  3. Cagrilintide + semaglutide (CagriSema)

    Research use only
    Randomized trials

    Evidence strength: Randomized trials. Randomized controlled trials in humans, at scale.

    What it is
    An amylin analog paired with semaglutide, targeting two separate satiety pathways in one weekly injection.
    What the evidence shows
    The 2026 network meta-analysis placed the combination at −17.84% mean weight reduction, essentially level with tirzepatide 15 mg at −17.97%, and ahead of everything else at the 20%-or-more threshold.5
    The catch
    Not approved, so there is no legitimate prescription route to it yet. Cagrilintide on its own performed well below the combination — buying the amylin half from a grey-market seller is not a cheap version of this result.

    Sold for laboratory use. Not a legal medicine for people.

  4. Tesamorelin (Egrifta)

    FDA-approved
    Randomized trials

    Evidence strength: Randomized trials. Randomized controlled trials in humans, at scale.

    What it is
    A growth-hormone-releasing factor analog, approved for one narrow use: excess visceral abdominal fat in people with HIV-associated lipodystrophy.
    What the evidence shows
    The pivotal NEJM trial found it reduced visceral adipose tissue in that population, which is what its approval covers.6
    The catch
    It is approved for a specific condition, not for general weight loss, and it moves visceral fat rather than the number on the scale. If you do not have HIV-associated lipodystrophy, no evidence here applies to you.

    Approved for this use and available by prescription.

  5. Retatrutide

    Research use only
    Early human

    Evidence strength: Early human. Small, open-label, or phase 1/2 trials. Promising, unproven.

    What it is
    A triple agonist — GIP, GLP-1 and glucagon receptors — from Eli Lilly. Still in trials.
    What the evidence shows
    A phase 2 trial in 338 adults reported a mean −24.2% at 48 weeks on the 12 mg dose against −2.1% on placebo, the largest figure yet published for a drug in this class.4
    The catch
    Phase 2 is 338 people, not the tens of thousands a phase 3 program enrolls, and 48 weeks is not a lifetime of use. It is not approved, so nothing you can buy today labeled 'retatrutide' came from Lilly. Wait for it, or take one of the approved options above.

    Sold for laboratory use. Not a legal medicine for people.

  6. CJC-1295 and ipamorelin

    Compounding restricted
    Animal only

    Evidence strength: Animal only. Rodent or cell studies. Nothing published in humans.

    What it is
    Two growth-hormone secretagogues, usually sold together as a blend, marketed on the premise that more growth hormone means more fat burned.
    What the evidence shows
    CJC-1295 does what it says on the mechanism: a 2006 trial in healthy adults showed it raises growth hormone and IGF-1 for days after a dose. What no trial shows is that this produces weight loss.7,8
    The catch
    Raising a hormone is not the same as changing a body. There is no human weight-loss outcome trial for either compound, and peptide compounding is under active FDA restriction — compliant pharmacies decline to sell these.

    Under active FDA restriction — compliant pharmacies decline to sell it.

  7. MOTS-c

    Research use only
    Animal only

    Evidence strength: Animal only. Rodent or cell studies. Nothing published in humans.

    What it is
    A peptide encoded in mitochondrial DNA, studied for its effects on metabolism and insulin sensitivity.
    What the evidence shows
    The metabolic work is in rodents and cell models. It appears in the 2026 review of unapproved peptides on exactly that basis — favorable animal metabolic outcomes, scarce human safety data.8
    The catch
    Nothing published tells you what it does to body weight in a person. Sold for research use, which is a legal category, not a quality standard.

    Sold for laboratory use. Not a legal medicine for people.

  8. AOD-9604

    Research use only
    Anecdotal

    Evidence strength: Anecdotal. User reports and forum consensus. No controlled data.

    What it is
    A fragment of human growth hormone, sold specifically as a fat-loss peptide. The name is short for 'anti-obesity drug 9604.'
    What the evidence shows
    There is no published human weight-loss efficacy trial for it. A 2026 review of unapproved peptides sold direct to patients covers AOD-9604 among compounds where favorable animal results have not been matched by rigorous human data.8
    The catch
    A compound named after the outcome it is sold for, with no trial demonstrating that outcome. The same review notes the placebo effect as a real mediator of perceived peptide efficacy, amplified by social media — which is most of what you will find if you search for results.

    Sold for laboratory use. Not a legal medicine for people.

How to read the evidence meter

Four steps, weakest to strongest. Most peptides sold for a goal light up one. We show the step the published human evidence actually reaches — not the step the seller implies.

  1. AnecdotalUser reports and forum consensus. No controlled data.
  2. Animal onlyRodent or cell studies. Nothing published in humans.
  3. Early humanSmall, open-label, or phase 1/2 trials. Promising, unproven.
  4. Randomized trialsRandomized controlled trials in humans, at scale.

Why the honest list is this short

Search "peptides for weight loss" and you will get a dozen names. Four of them have human trials measuring weight as the outcome, and all four work on the same gut-hormone system. Everything else on the usual list either has animal data, a mechanism study showing a hormone moved, or nothing at all.

That is not a gap in the research anyone is about to close. Running a weight-loss trial costs tens of millions of dollars, and it only happens when a company owns the molecule and intends to sell it as a drug. Compounds circulating on the grey market have no such sponsor, so the trial never gets funded, and the absence of evidence is permanent rather than temporary.

The number nobody puts in the headline

The interesting figure in the semaglutide literature is not the 14.9%. It is what the trial extension found a year after people stopped: 11.6 of the lost percentage points came back, and the cardiometabolic gains reverted toward where they started.

Read that as a cost, because it is one. These drugs work while you take them. Budget for continuing, or budget for the regain — those are the two options, and a provider who does not raise this with you is selling rather than treating.

Growth hormone is not a shortcut

Most non-GLP-1 peptides sold for fat loss share one pitch: raise growth hormone, burn more fat. CJC-1295 genuinely does raise growth hormone and IGF-1, and that is the trial people cite for it.

But the trial measured hormones, not people's weight. A drug can move a biomarker convincingly and do nothing to the outcome you actually care about — that is a routine result in drug development, not a rare one. Until somebody runs the weight trial, the honest answer for this whole category is that we do not know, and the sellers do not know either.

What restricted availability actually means

Several compounds here are labeled research use only. That is a legal category describing what a seller may ship without a prescription. It is not a quality tier, a purity guarantee, or a signal that approval is coming.

Peptide compounding is separately under active FDA restriction, and pharmacies that intend to stay compliant have stopped selling the affected compounds. If a site is happy to sell you one anyway, that tells you something about the site.

Frequently asked questions

What is the best peptide for weight loss?

Tirzepatide produced the largest weight reduction of any approved option in trials — a mean of −20.9% at 72 weeks on the 15 mg dose — and a 2026 network meta-analysis of 25 trials ranked it first in the class. Semaglutide is the most studied. Both require a prescription, and both are the same trade-off: they work while you take them.

Do peptides like BPC-157 or AOD-9604 help you lose weight?

There is no published human weight-loss efficacy trial for AOD-9604, despite it being named and sold as an anti-obesity compound. Peptides outside the GLP-1 class do not have weight-loss outcome trials behind them, and peptide compounding is currently under FDA restriction.

Will I regain the weight if I stop?

In the STEP 1 trial extension, participants regained 11.6 of the percentage points they had lost within a year of stopping semaglutide, turning a 17.3% loss into a 5.6% one, and most cardiometabolic improvements moved back toward baseline. Plan for continued treatment or plan for regain.

Are GLP-1 drugs peptides?

Yes. Semaglutide is a 31-amino-acid peptide and tirzepatide is 39. The distinction people draw between 'peptides' and 'GLP-1s' is a marketing one, not a chemical one — the difference that matters is that GLP-1 drugs went through trials.

References

  1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/
  2. Wilding JPH, Batterham RL, Davies M, et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. https://pubmed.ncbi.nlm.nih.gov/35441470/
  3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/35658024/
  4. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/37366315/
  5. Hamarsheh S, Jaber AR, Abu-Khazneh O, et al. (2026). Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials. Endocrinology, Diabetes & Metabolism. https://pubmed.ncbi.nlm.nih.gov/42207966/
  6. Falutz J, Allas S, Blot K, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/18057338/
  7. Teichman SL, Neale A, Lawrence B, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism. https://pubmed.ncbi.nlm.nih.gov/16352683/
  8. Mendias CL, Awan TM (2026). Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. https://pubmed.ncbi.nlm.nih.gov/41966639/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.